R-ICE salvage with autoSCT consolidation (relapsed/refractory PMBCL)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | None declared |
|---|
| ID | REG-R-ICE-PMBCL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Notes
Standard salvage for chemosensitive r/r PMBCL. Rituximab + ICE × 2-3 cycles → response assessment (PET) → BEAM-conditioning autoSCT if PR/CR. ~50-60% achieve durable remission post-autoSCT. CAR-T (axi-cel/liso-cel) is alternative for chemorefractory or post-autoSCT relapse. Pembrolizumab also active in r/r PMBCL (KEYNOTE-170).
Used By
Indication
IND-PMBCL-2L-RICE-AUTOSCT- IND-PMBCL-2L-RICE-AUTOSCT